5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine,
PLX3397,
Pexidartinib,
1029044-16-3,
Pexidartinib (PLX3397),
PLX3397,
PLX-3397,
UNII-6783M2LV5X,
CHEMBL3813873,
CML-261,
6783M2LV5X,
PLX 3397,
5-((5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine,
5-[(5-Chloro-1h-Pyrrolo[2,3-B]pyridin-3-Yl)methyl]-N-{[6-(Trifluoromethyl)pyridin-3-Yl]methyl}pyridin-2-Amine,
Pexidartinib [INN],
5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine,
Pexidartinib [USAN],
pexidartinib-plx3397,
Pexidartinib(PLX3397),
Pexidartinib(PLX-3397),
GTPL8710,
SCHEMBL1267310,
EX-A589,
BCP15183,
BDBM50177716,
MFCD28900745,
s7818,
AKOS026750359,
ZINC115705166,
DB12978,
SB19178,
NCGC00480774-06,
3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-,
AC-30300,
AK475466,
BC600738,
DA-48267,
HY-16749,
B5854,
FT-0699505,
J-690008,
2(S)-Amino-3-(4-{2-amino-6-[2,2,2-trifluoro-1-(3'-fluoro-biphenyl-4-yl)-ethoxy]-pyrimidin-4-yl}-phenyl)-propionic acid hydrochloride,
5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)-3-pyridyl]methyl]pyridin-2-amine,
N-[5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-3-pyridinemethanamine,
Pexidartinib hydrochloride,
CS-4256,
A15520,
3-Pyridinemethanamine, N-[5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-,
P31,